Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.43 |
| ▸ | GABRP | O00591 | 4/20 | 0.43 |
| ▸ | GABRD | O14764 | 4/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.43 |
| ▸ | GABRE | P78334 | 4/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15670153 | 0.89 | CYP1A2 (0.42) | NPC1SMN1; SMN2RAB9ACYP1A2GABRA1 | |
| SCHEMBL15669996 | 0.87 | KMT2A (0.44) | NPC1SMN1; SMN2RAB9ACYP1A2GABRA1 | |
| SCHEMBL286756 | 0.85 | MAPK1 (0.53) | NPC1SMN1; SMN2RAB9ACYP1A2LMNA | |
| SCHEMBL9901416 | 0.85 | CYP1A2 (0.51) | NPC1SMN1; SMN2RAB9ACYP1A2GABRA1 | |
| SCHEMBL11887383 | 0.84 | NPC1 (0.55) | NPC1SMN1; SMN2RAB9ACYP1A2LMNA | |
| SCHEMBL20204014 | 0.83 | NPC1 (0.51) | NPC1SMN1; SMN2RAB9ALMNAKDM4E | |
| SCHEMBL27039792 | 0.82 | CACNA1I (0.45) | NPC1SMN1; SMN2RAB9ACYP1A2LMNA | |
| SCHEMBL29601148 | 0.82 | CACNA1I (0.45) | NPC1SMN1; SMN2RAB9ACYP1A2LMNA | |
| SCHEMBL20204015 | 0.82 | NPC1 (0.44) | NPC1SMN1; SMN2RAB9ALMNAMEN1 | |
| SCHEMBL5440798 | 0.81 | POLB (0.57) | NPC1SMN1; SMN2RAB9ACYP1A2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| CN-106795147-B | Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use | 美国安进公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| CN-106795147-A | Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use | 美国安进公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160046618-A1 | Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use | AMGEN INC. (US) | 2016-02-18 | — | — | US | disclosed |
| CN-105254557-A | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC | 2016-01-20 | — | — | CN | disclosed |
| CN-105130957-A | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC | 2015-12-09 | — | — | CN | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| WO-2010137351-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | NPC1 1282/4885SMN1; SMN2 700/4885RAB9A 1179/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | NPC1 1302/4885SMN1; SMN2 708/4885RAB9A 1188/4885 |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | NPC1 218/4885SMN1; SMN2 334/4885RAB9A 901/4885 |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | NPC1 1171/4885SMN1; SMN2 3291/4885RAB9A 382/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | NPC1 218/4885SMN1; SMN2 334/4885RAB9A 901/4885 |
| US-20160046618-A1 | Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use | BACE1, BACE2, APP | NPC1 1171/4885SMN1; SMN2 3291/4885RAB9A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.